192 related articles for article (PubMed ID: 6828303)
21. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients.
Pavlidis NA; Petris C; Briassoulis E; Klouvas G; Psilas C; Rempapis J; Petroutsos G
Cancer; 1992 Jun; 69(12):2961-4. PubMed ID: 1591689
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen and ocular toxicity.
Ah-Song R; Sasco AJ
Cancer Detect Prev; 1997; 21(6):522-31. PubMed ID: 9398992
[TBL] [Abstract][Full Text] [Related]
23. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
[TBL] [Abstract][Full Text] [Related]
24. Ocular toxicity from systemic drug therapy. An overview of clinically important adverse reactions.
Davidson SI; Rennie IG
Med Toxicol; 1986; 1(3):217-24. PubMed ID: 3784843
[No Abstract] [Full Text] [Related]
25. Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.
Eaton JS; Miller PE; Mannis MJ; Murphy CJ
J Ocul Pharmacol Ther; 2015 Dec; 31(10):589-604. PubMed ID: 26539624
[TBL] [Abstract][Full Text] [Related]
26. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.
Kheir WJ; Sniegowski MC; El-Sawy T; Li A; Esmaeli B
Surv Ophthalmol; 2014; 59(5):493-502. PubMed ID: 25130892
[TBL] [Abstract][Full Text] [Related]
27. Clinically important ocular reactions to systemic drug therapy.
Rennie IG
Drug Saf; 1993 Sep; 9(3):196-211. PubMed ID: 8240725
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen-associated eye disease. A review.
Nayfield SG; Gorin MB
J Clin Oncol; 1996 Mar; 14(3):1018-26. PubMed ID: 8622006
[TBL] [Abstract][Full Text] [Related]
29. Update on ocular complications of systemic cancer chemotherapy.
Schmid KE; Kornek GV; Scheithauer W; Binder S
Surv Ophthalmol; 2006; 51(1):19-40. PubMed ID: 16414359
[TBL] [Abstract][Full Text] [Related]
30. [Recently recognized ophthalmic complications of systemic treatments].
Rousseau A; Labetoulle M
J Fr Ophtalmol; 2015 Nov; 38(9):876-82. PubMed ID: 26507783
[TBL] [Abstract][Full Text] [Related]
31. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.
Dranko S; Kinney C; Ramanathan RK
Clin Colorectal Cancer; 2006 Sep; 6(3):224-5. PubMed ID: 17026793
[TBL] [Abstract][Full Text] [Related]
32. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
[TBL] [Abstract][Full Text] [Related]
33. Ocular toxicities of epidermal growth factor receptor inhibitors and their management.
Basti S
Cancer Nurs; 2007; 30(4 Suppl 1):S10-6. PubMed ID: 17666986
[TBL] [Abstract][Full Text] [Related]
34. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction.
Mansur C; Pfeiffer ML; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(1):9-12. PubMed ID: 27429222
[TBL] [Abstract][Full Text] [Related]
35. Dacryoscintigraphy for the detection of ocular drainage system stenosis induced by docetaxel and fluorouracil.
Tsoucalas GI; Tzovaras AA; Ntokou AP; Markos LI; Sarafianou EN
Hell J Nucl Med; 2012; 15(2):159-61. PubMed ID: 22741155
[No Abstract] [Full Text] [Related]
36. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.
Fraunfelder FW; Fraunfelder FT
Ophthalmology; 2004 Jul; 111(7):1275-9. PubMed ID: 15234126
[TBL] [Abstract][Full Text] [Related]
37. Long-term tamoxifen citrate use and potential ocular toxicity.
Gorin MB; Day R; Costantino JP; Fisher B; Redmond CK; Wickerham L; Gomolin JE; Margolese RG; Mathen MK; Bowman DM; Kaufman DI; Dimitrov NV; Singerman LJ; Bornstein R; Wolmark N
Am J Ophthalmol; 1998 Apr; 125(4):493-501. PubMed ID: 9559735
[TBL] [Abstract][Full Text] [Related]
38. [The pathology of ocular syndromes caused by toxicity].
Lasudry J
Bull Soc Belge Ophtalmol; 2007; (304):155-78. PubMed ID: 17718241
[TBL] [Abstract][Full Text] [Related]
39. Screening for tamoxifen ocular toxicity: a prospective study.
Therssen R; Jansen E; Leys A; Rutten J; Meyskens J
Eur J Ophthalmol; 1995; 5(4):230-4. PubMed ID: 8963159
[TBL] [Abstract][Full Text] [Related]
40. The national registry of drug-induced ocular side effects.
Fraunfelder FT; Meyer SM
Aust J Ophthalmol; 1984 May; 12(2):129-31. PubMed ID: 6487182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
